24/7 Market News Snapshot 26 December, 2024 – Hoth Therapeutics, Inc. Common Stock (NASDAQ:HOTH)

December 26, 2024

DENVER, Colo., 26 December, 2024 (247marketnews.com) – (NASDAQ:HOTH) are discussed in this article.
Hoth Therapeutics, Inc. (HOTH), a biopharmaceutical innovator focused on developing advanced therapies, is currently experiencing a positive momentum in the pre-market trading session. Shares are priced at $0.796, reflecting a 1.14% increase from the previous close of $0.787, driven by significant trading volume of 6.43 million shares. This upward trend indicates heightened investor interest and may correlate with the company’s recent announcement of a transformative exclusive patent license agreement with the U.S. Department of Veterans Affairs (VA).

This agreement grants Hoth exclusive rights to a pioneering patent portfolio developed in conjunction with Emory University, aimed at addressing critical issues related to obesity and related health disorders. This collaborative innovation is poised to significantly advance Hoth’s mission of providing groundbreaking healthcare solutions. The company is keen on leveraging its resources to commercialize this promising technology, marking a crucial step in the fight against obesity.

In commenting on the partnership, Robb Knie, CEO of Hoth Therapeutics, emphasized the importance of this collaboration in addressing obesity and its associated health challenges, promising the advancement of science-driven solutions to benefit patients globally. Furthermore, Hoth is also committed to expanding its intellectual property portfolio with a Letter of Intent (LOI) to acquire additional provisional patent protection for its lead therapeutic, HT-001, thereby enriching its therapeutic applications in oncology.

The recent developments suggest that investors should keep a close eye on resistance levels above $0.80 and support lines near $0.78, as Hoth Therapeutics continues to forge strategic partnerships and innovate within the healthcare landscape. The company remains dedicated to enhancing patient outcomes through effective and innovative therapies, reinforcing its position at the forefront of biopharmaceutical advancement.

Related news for (HOTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.